New pill combo aims to melt heart plaque in High-Risk patients
NCT ID NCT06305559
First seen Apr 12, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This study tests whether a daily pill combining obicetrapib and ezetimibe can reduce fatty plaque buildup in the heart arteries of 300 adults with high-risk heart disease. Participants must already be on maximum tolerated cholesterol medication and have significant plaque visible on a CT scan. The treatment is taken long-term to control disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NGMR
Hialeah, Florida, 33016, United States
Conditions
Explore the condition pages connected to this study.